camrelizumab
roche,jiangsu hengrui pharmaceuticals
['mibc', 'nct02710734', 'urothelial', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cam ', 'bladder', 'roche,(-broche),(-rocheter)']
astonishing work by dr. geynisman :
phii allocation trial of risk enabled therapy after nac for #bladdercancer a promising role for active surveillance!
#gu23 
Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow